Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Lotiglipron

Stage Phase 2Stale

Sponsor Pfizer

Route oral and injection

Class GLP-1 RA

Mechanism GLP-1 receptor agonist

Sources

registry, as of 2024-08-09Stale

https://clinicaltrials.gov/study/NCT05671653

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range. Overall status TERMINATED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 32. Conditions Obesity. Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide. The effect of these GLP-1 drugs on a single dose of the common sedative medication midazolam blood levels will be measured. The effect of chronic PF-0

ClinicalTrials.gov NCT05671653 protocol and results modules

registry, as of 2024-11-15Stale

https://clinicaltrials.gov/study/NCT05788328

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants. Overall status TERMINATED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 16. Conditions Healthy. The purpose of the study was to understand the effect of PF-07081532 on the movement of Dabigatran and Rosuvastatin into, though, and out of the body in healthy overweight or obese adult participants. This study also aims to collect data on safety and how tolerable the study medi

ClinicalTrials.gov NCT05788328 protocol and results modules

registry, as of 2024-09-23Stale

https://clinicaltrials.gov/study/NCT05745701

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 16. Conditions Healthy. This is a Phase 1, open-label, fixed-sequence, 3-period study to evaluate the effect of multiple doses of itraconazole and a single dose of cyclosporine on the single-dose PK of PF-07081532 in otherwise healthy, overweight or obese, adult female and male participants. The 3 stud

ClinicalTrials.gov NCT05745701 protocol and results modules

registry, as of 2024-08-01Stale

https://clinicaltrials.gov/study/NCT05579977

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity. Overall status TERMINATED. Phases PHASE2. Lead sponsor Pfizer. Enrollment 902. Conditions Diabetes Mellitus; Obesity. The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metf

ClinicalTrials.gov NCT05579977 protocol and results modules

registry, as of 2024-08-12Stale

https://clinicaltrials.gov/study/NCT05158244

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 34. Conditions Type 2 Diabetes Mellitus. This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532. Study participants will receive the investigational product or placebo every day for 42 days. The purpose of the study is to evaluate the s

ClinicalTrials.gov NCT05158244 protocol and results modules

registry, as of 2024-08-09Stale

https://clinicaltrials.gov/study/NCT05677867

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 20. Conditions Overweight; Obesity. The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese. All study participants will receive a total of 2 single

ClinicalTrials.gov NCT05677867 protocol and results modules

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05671653

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in

NCT05671653 description or intervention text

Studies

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Dru

Registry NCT05671653

Phase Phase 1

Status Terminated

Enrollment 32

Start 2023-01-19

Primary completion 2023-11-03

Study completion 2023-11-03

Cohort 1: PF-07081532

Population Obesity

Cohort 2: Semaglutide

Population Obesity

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

Registry NCT05788328

Phase Phase 1

Status Terminated

Enrollment 16

Start 2023-03-27

Primary completion 2023-09-11

Study completion 2023-09-11

Period 1

Regimen daily

Population Healthy

Period 2

Regimen daily

Population Healthy

Period 3

Regimen daily

Population Healthy

Period 4

Regimen daily

Population Healthy

Period 5

Regimen daily

Population Healthy

Period 6

Regimen daily

Population Healthy

Period 7

Regimen daily

Population Healthy

Period 8

Regimen daily

Population Healthy

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

Registry NCT05745701

Phase Phase 1

Status Completed

Enrollment 16

Start 2023-02-22

Primary completion 2023-05-29

Study completion 2023-05-29

Period 1: PF-07081532

Regimen daily

Population Healthy

Period 2: Cyclosporine + PF-07081532

Regimen daily

Population Healthy

Period 3: Itraconazole + PF-07081532

Regimen daily

Population Healthy

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

Registry NCT05579977

EudraCT 2022-002834-15

Phase Phase 2

Status Terminated

Enrollment 902

Start 2022-10-27

Primary completion 2023-07-14

Study completion 2023-09-22

PF-07081532 20 mg T2DM

Dose 20 mg

Regimen daily

Weeks 36

Comparator placebo

Population Diabetes Mellitus; Obesity

PF-07081532 40 mg T2DM

Dose 40 mg

Regimen daily

Weeks 36

Comparator placebo

Population Diabetes Mellitus; Obesity

PF-07081532 80 mg T2DM

Dose 80 mg

Regimen daily

Weeks 36

Comparator placebo

Population Diabetes Mellitus; Obesity

PF-07081532 160 mg T2DM

Dose 160 mg

Regimen daily

Weeks 36

Comparator placebo

Population Diabetes Mellitus; Obesity

PF-07081532 260 mg T2DM

Dose 260 mg

Regimen daily

Weeks 36

Comparator placebo

Population Diabetes Mellitus; Obesity

Placebo T2DM

Regimen daily

Weeks 36

Population Diabetes Mellitus; Obesity

PF-07081532 80 mg Obesity

Dose 80 mg

Regimen daily

Weeks 36

Comparator placebo

Population Diabetes Mellitus; Obesity

PF-07081532 140 mg Obesity

Dose 140 mg

Regimen daily

Weeks 36

Comparator placebo

Population Diabetes Mellitus; Obesity

PF-07081532 200 mg Obesity (Option 1)

Dose 200 mg

Regimen daily

Weeks 36

Comparator placebo

Population Diabetes Mellitus; Obesity

PF-07081532 200 mg Obesity (Option 2)

Dose 200 mg

Regimen daily

Weeks 36

Comparator placebo

Population Diabetes Mellitus; Obesity

PF-07081532 260 mg Obesity

Dose 260 mg

Regimen daily

Weeks 36

Comparator placebo

Population Diabetes Mellitus; Obesity

Rybelsus 14 mg T2DM

Dose 14 mg

Regimen daily

Weeks 36

Comparator placebo

Population Diabetes Mellitus; Obesity

Placebo Obesity

Regimen every 4 weeks

Weeks 36

Population Diabetes Mellitus; Obesity

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Registry NCT05158244

Phase Phase 1

Status Completed

Enrollment 34

Start 2021-12-22

Primary completion 2022-06-15

Study completion 2022-06-15

PF-07081532

Regimen once daily

Comparator placebo

Population Type 2 Diabetes Mellitus

Placebo

Regimen once daily

Population Type 2 Diabetes Mellitus

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Registry NCT05677867

Phase Phase 1

Status Completed

Enrollment 20

Start 2023-01-18

Primary completion 2023-03-14

Study completion 2023-03-14

Formulation A (Reference) followed by Formulation B (Test)

Population Overweight; Obesity

Formulation B (Test) followed by Formulation A (Reference)

Population Overweight; Obesity